Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective Trial of Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic (CAE-L) in Individuals With Schizophrenia or Schizoaffective Disorder at Risk for Treatment Non-adherence and for Homelessness
Brief Summary: Psychotropic medications are a cornerstone of treatment for individuals with schizophrenia and schizoaffective disorder, however rates of full or partial non-adherence can exceed 60%. Inadequate adherence is associated with poor outcomes such as relapse, homelessness, hospitalization, and increased health care costs. Studies have shown a direct correlation between non-adherence and rates of relapse in schizophrenia; on average, non-adherent patients have a risk of relapse that is 3.7 times greater than their adherent counterparts. A major obstacle to good outcomes in the maintenance treatment of patients with severe mental illness is difficulty with medication routines on an on-going basis. For this reason, long-acting injectable antipsychotic medication is a particularly attractive treatment option for populations with schizophrenia and schizoaffective disorder, although it is unlikely that medication treatment alone is likely to modify long-term attitudes and behaviors.

This prospective study is a pilot analysis of a combined approach which merges a psychosocial intervention to optimize treatment attitudes towards psychotropic medication (CAE) and long-acting injectable antipsychotic medication (L) in recently homeless individuals with schizophrenia or schizoaffective disorder who are known to have on-going difficulties with treatment non-adherence. It is expected that this combined approach (CAE-L) will improve illness outcomes among the most vulnerable of populations with schizophrenia or schizoaffective disorder.


Options:
A: Arm Label: Extended-release naltrexone (XR-NTX); Type: ACTIVE_COMPARATOR; Interventions: Drug: Extended-Release Naltrexone | Arm Label: Motivational Enhancement Counseling Only; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Motivational Enhancement Counseling | Intervention Type: DRUG; Name: Extended-Release Naltrexone; Assigned to Arm(s): Extended-release naltrexone (XR-NTX) | Intervention Type: BEHAVIORAL; Name: Motivational Enhancement Counseling; Assigned to Arm(s): Motivational Enhancement Counseling Only
B: Arm Label: Depot Naltrexone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Depot naltrexone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Treatment as Usual (TAU) | Intervention Type: DRUG; Name: Depot naltrexone; Assigned to Arm(s): Depot Naltrexone | Intervention Type: OTHER; Name: Treatment as Usual (TAU); Assigned to Arm(s): Placebo
C: Arm Label: Patient Noncompliance; Type: EXPERIMENTAL; Interventions: Drug: haloperidol decanoate, Drug: haloperidol, Behavioral: Customized Adherence Enhancement | Intervention Type: DRUG; Name: haloperidol decanoate; Assigned to Arm(s): Patient Noncompliance | Intervention Type: DRUG; Name: haloperidol; Assigned to Arm(s): Patient Noncompliance | Intervention Type: BEHAVIORAL; Name: Customized Adherence Enhancement; Assigned to Arm(s): Patient Noncompliance
D: Arm Label: Extended-Release Naltrexone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Extended-Release Naltrexone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Extended-Release Naltrexone | Intervention Type: DRUG; Name: Extended-Release Naltrexone; Assigned to Arm(s): Extended-Release Naltrexone, Placebo

Answer: C